Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 13 970 / https://doi.org/10.3332/ecancer.2019.970

Case Report

Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure

Osimertinib is a first-line treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harbouring EGFR mutations. Pneumonitis is a severe adverse event (AE) related to osimertinib treatment which appears to be more frequent when associated with concurrent or previous anti-PD(L)1 exposure. Data regarding the efficacy and safety of osimertinib rechallenge, especially in the setting of central nervous system (CNS) metastases, are scarce. We herein describe a case of a 53-year-old patient with metastatic EGFR-mutated NSCLC, who developed pneumonitis after osimertinib treatment and was successfully rechallenged with 40 mg daily osimertinib, with CNS response. This dose reduction strategy may be an option for selected patients with brain metastases after tyrosine kinase inhibitors-induced AEs.

Keywords: lung cancer, osimertinib, immunotherapy, pneumonitis, rechallenge, brain metastases

Loading Article Metrics ... Please wait

Related articles

Research: Awareness of human papilloma virus and cervical cancer prevention among Cypriot female healthcare workers

Abstract | Full Article | PDF Published: 20 Nov 2019 / https://doi.org/10.3332/ecancer.2019.978

Case Report: Case report of a 65-year-old man with biatrial metastatic localisation from poorly differentiated cutaneous squamous cell carcinoma

Abstract | Full Article | PDF Published: 19 Nov 2019 / https://doi.org/10.3332/ecancer.2019.977

Conference Report: Towards universal coverage—highlights from the 2nd Uganda Conference on Cancer and Palliative Care, 5–6 September 2019, Kampala, Uganda

Abstract | Full Article | PDF Published: 12 Nov 2019 / https://doi.org/10.3332/ecancer.2019.976

Short Communication: Elimination of cervical cancer: challenges for developing countries

Abstract | Full Article | PDF Published: 12 Nov 2019 / https://doi.org/10.3332/ecancer.2019.975

Review: Barriers to the composition and implementation of advance directives in oncology: a literature review

Abstract | Full Article | PDF Published: 12 Nov 2019 / https://doi.org/10.3332/ecancer.2019.974



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation